NexImmune 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Craig Jalbert

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	3.3yrs
이사회 평균 재임 기간	3.5yrs

최근 관리 업데이트

Recent updates

NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Sep 07

Neximmune GAAP EPS of -$0.69 misses by $0.01

Aug 15

NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers

Jul 14

NexImmune: Selling For Under Cash Value

May 31

Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation

May 26

We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate

Dec 19

CEO

Craig Jalbert (62 yo)

less than a year

테뉴어

Mr. Craig R. Jalbert serve as a CEO, President, Chief Financial Officer, Treasurer and Secretary and sole member of the board since November 2024 at TFF Pharmaceuticals, Inc. He is President, Treasurer, CS...

리더십 팀

이름	위치	테뉴어	보상	소유권
John Trainer	Consultant	1.2yrs	US$1.35m	데이터 없음
Craig Jalbert	President	less than a year	데이터 없음	데이터 없음
Karen Haslbeck	Head of Human Resources	no data	데이터 없음	데이터 없음
Daniel Bednarik	Senior Vice President of Molecular Engineering & Protein Design	7.5yrs	데이터 없음	데이터 없음
Robert Knight	Chief Medical Officer	3.8yrs	US$2.91m	0% $ 0
Chad Rubin	Senior Vice President of Corporate Affairs	3.6yrs	데이터 없음	데이터 없음
Jack Ragheb	Senior Vice President of Translational Science	3.3yrs	데이터 없음	데이터 없음
Matthew Schiller	Head of Business Development	3.3yrs	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 관리: NEXI 의 관리팀은 경험 ( 3.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Gerald Nepom	Chair of Autoimmune & Infectious Disease Scientific Advisory Board	2.8yrs	데이터 없음	데이터 없음
Jeffrey Weber	Chief Scientific Advisor	3.5yrs	데이터 없음	데이터 없음
Anil Rustgi	Member of Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Jonathan Schneck	Co-Chairman of Scientific Advisory Board	12.8yrs	데이터 없음	데이터 없음
Paul Richardson	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Marcela Maus	Member of Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Miguel-Angel Perales	Member of Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Kevan Herold	Member of Scientific Advisory Board and Autoimmune & Infectious Disease Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Juan Varela	Member of Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Michelle Krogsgaard	Member of Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Yi Lin	Member of Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Andreas Mackensen	Member of Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

경험이 풍부한 이사회: NEXI 의 이사회는 경험(평균 재직 기간 3.5 년)으로 간주됩니다.

NexImmune 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

High number of new directors

NexImmune, Inc. Announces Executive Changes, Effective as of September 2, 2023

NexImmune, Inc. Announces John Trainer, Chief Financial Officer to Depart, Effective September 2, 2023

Independent Chairman of the Board recently bought US$164k worth of stock

High number of new directors

Independent Chairman of the Board recently bought US$96k worth of stock

Recent updates

The Nasdaq Stock Market to Delist Common Stock of NexImmune

Nasdaq Determines to Delist NexImmune Shares of Common Stock

Nasdaq Determines to Delist NexImmune Shares of Common Stock

NexImmune, Inc. announced delayed 10-Q filing

NexImmune, Inc. announced delayed annual 10-K filing

High number of new directors

NexImmune, Inc. has completed a Follow-on Equity Offering in the amount of $3.672009 million.

NexImmune Receives Notice from Nasdaq Pursuant to Nasdaq Listing Rule 5101

NexImmune, Inc. announced delayed 10-Q filing

NexImmune Regains Compliance with the Minimum Closing Bid Price Requirement

NexImmune, Inc. Approves 1 for 25 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

NexImmune, Inc. Announces Executive Changes, Effective as of September 2, 2023

NexImmune, Inc. Announces John Trainer, Chief Financial Officer to Depart, Effective September 2, 2023

New major risk - Financial position

Neximmune Announces Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-Hsct Aml At the American Society of Clinical Oncology 2023 Annual Meeting

Independent Chairman of the Board recently bought US$164k worth of stock

Price target decreased by 30% to US$2.43

High number of new directors

Independent Chairman of the Board recently bought US$96k worth of stock

Price target decreased to US$2.43

High number of new directors

NexImmune Receives Deficiency Letter from the Listing Qualifications Department of Nasdaq

NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Neximmune GAAP EPS of -$0.69 misses by $0.01

NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers

NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers

NexImmune, Inc.(NasdaqGM:NEXI) dropped from Russell 2500 Value Index

Independent Director recently bought US$298k worth of stock

Price target decreased to US$14.75

NexImmune: Selling For Under Cash Value

Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation

NexImmune Inc. Appoints Leena Gandhi to Board of Directors as a Non-Executive Director

NexImmune, Inc., Annual General Meeting, Jun 13, 2022

High number of new and inexperienced directors

Neximmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center's Herbert Irving Comprehensive Cancer Center

Neximmune, Inc. Promotes Mathias Oelke, Ph.D., to Chief Scientific Officer

NexImmune, Inc. Announces Management Changes

Independent Director exercised options to buy US$338k worth of stock.

We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate

Independent Director has left the company

NexImmune, Inc. has completed an IPO in the amount of $110.007 million.

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간